Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Hansa Biopharma
Hansa Biopharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Idefirix
Imlifidase
2020-08-25
Kidney transplantation
,
Immunologic desensitization
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Imlifidase
healthy volunteers/patients
,
duchenne muscular dystrophy
,
muscular dystrophies
,
kidney diseases
,
graft rejection
,
renal insufficiency
,
chronic kidney failure
,
guillain-barre syndrome
,
thrombotic thrombocytopenic purpura
,
thrombocytopenic purpura
,
purpura
,
retinal diseases
,
chronic renal insufficiency
,
cardiomyopathies
,
crigler-najjar syndrome
,
kidney transplantation
,
syndrome
,
anti-glomerular basement membrane disease
Albumin
graft rejection
Sodium chloride
graft rejection
Bevifimod
syndrome
,
anti-glomerular basement membrane disease
Pbs
healthy volunteers/patients
Octagam
kidney transplantation
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use